Adalimumab ELISA Kit (DEIABL221)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
Serum, plasma
Species Reactivity
Human
Intended Use
Adalimumab ELISA has been especially developed for the quantitative analysis of free adalimumab in serum and plasma samples.
Storage
The kit is shipped at ambient temperature (10-30°C) and should be stored at 2-8°C for long term storage. Keep away from heat or direct sunlight. The strips of microtiter plate are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.
Precision
Intra-assay and inter-assay CVs <30%.
Sensitivity
The lowest detectable level (Lowest detection limit, LOD) that can be distinguished from the zero standard is 3 ng/mL.
General Description
Adalimumab binds with specificity to tumour necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface tumour necrosis factor expressing cells in vitro when in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (Tumour necrosis factorbeta). TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses. Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and the joint destruction that are major complications of these diseases. Increased levels of TNF are also measured in psoriasis plaques. In plaque psoriasis, treatment with adalimumab may decrease the epidermal thickness and inflammatory cell infiltration. The relationship between this pharmacodynamics and the mechanism(s) by which adalimumab achieves its clinical effects is not known. Additionally, adalimumab alters biological responses that are induced/regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration during inflammation (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).

Citations


Have you cited DEIABL221 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Viguier, M; Livideanu, C; et al. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. JOURNAL OF DERMATOLOGICAL TREATMENT 25:75-77(2014).
Scott, FI; Osterman, MT; et al. Impact of JC Virus Antibody Testing in Patients with Crohn's Disease with Loss of Response to Infliximab: A Markov Model. INFLAMMATORY BOWEL DISEASES 19:2625-2633(2013).

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket